BIVV001, a novel fusion protein, has longer half-life than recombinant factor VIII products and may be a safe therapy for hemophilia A.
Investigators assessed whether there was a link between low bone mineral density, 25(OH)D concentrations, and bone turnover markers in hemophilia.
Inadvertent administration may result in serious adverse events.
ABO blood group has been associated with cardiovascular disease and thrombotic risk; however, influences on hemostasis are still not well understood.
In expanded research, investigators studied the effects of therapeutic and prophylactic anticoagulation treatment in hospitalized patients with COVID-19.
Researchers studied the effect of certain biomarkers on long-term adverse cardiovascular outcomes in patients with coronary morbidities undergoing PCI.
There is a need for novel, effective treatments for pediatric patients with hemophilia A with FVIII inhibitors to reduce annualized bleeding rates.
Investigators studied the frequency and risk factors linked to wound healing complications after elective orthopedic surgery in patients with hemophilia.
A team of investigators sought to determine whether endotheliopathy is involved in COVID-19–associated coagulopathy pathogenesis.
Investigators aimed to improve the understanding of the epidemiologic, clinical, and laboratory findings of cold agglutinin disease.
In addition to well-described platelet defects in gray platelet syndrome, immune defects, such as abnormal cells also exist.
A prospective, single-center study aimed to determine the prevalence of DVT after TKA among patients with hemophilia A and found that contrast-enhanced CT led to better detection compared with ultrasound.
In about 10% of pregnancies in which the mother has a congenital bleeding disorder, recommended fetal precautionary measures may influence the mode of delivery.
Researchers assessed whether hemophilia A disease registry could be used instead of clinical studies to determine orphan drug safety in pediatric patients.
There was a median bleeding score of 21 among patients with Glanzmann thrombasthenia, 9 in Bernard-Soulier syndrome, 10 in dense granule deficiency, 7 in ADP pathway defect, 8 in TxA2 pathway defect, 6 in isolated thrombocytopenia, and 8 in complex abnormalities.
Genetic mutations associated with the heterogeneity of hemophilia B Leyden may also be linked to mechanisms that increase factor IX levels with age.
VTE-BLEED prognostic scores did not accurately identify patients with VTE who were at high risk of bleeding events.
New developments in lab assays have allowed for more specialized assessments of VWD activity, leading to better diagnoses and various treatment options.
The percentage of discordance in onsite and off-site laboratory testing of von Willebrand disease remains high.
Sustained improvement was noted after the administration of tocilizumab, an interleukin-6 antagonist.
The exact number of hemophilia cases are unknown and estimates of the size and characteristics of the US hemophilia population are needed for healthcare planning and resource needs assessment.
Approximately 30% of patients with hemophilia are considered sporadic cases, causing a challenge when determining carrier status and disease transmission risk to offspring.
Concomitant use of dabigatran with verapamil or diltiazem was found to be associated with an increased risk of bleeding in patients with normal kidney function, according to the findings of a recently published retrospective cohort study.
Identifying hemophilia A in women and girls with factor VIII deficiency with bleeding events using healthcare claims still remains a challenge.
Researchers assessed 136 patients with VWD in Iran over 13 years to characterize clinical and molecular patterns associated with the disease.
The FDA has approved Sevenfact (coagulation factor VIIa [recombinant]-jncw; LFB Biotechnologies) for the treatment and control of bleeding episodes occurring in patients aged ≥12 years with hemophilia A or B with inhibitors.
The authors stated, however, that genetic screening should be used with caution in children.
Neither factor VIII clotting activity nor factor VIII antigens were significantly different for any blood group in patients with nonsevere hemophilia A.
Researchers found that exposure to opioids in patients with hemophilia may be underreported in the American Thrombosis and Hemostasis Network dataset.
Patients who experienced major adverse cardiovascular events reported higher von Willebrand factor plasma levels compared with patients in the control cohort.
Patients with hemophilia were found to experience worse general health but higher levels of psychological well-being compared with individuals in the control arm.
Novo Nordisk announced the launch of Esperoct® (antihemophilic factor [recombinant], glycopegylated-exei) for the treatment of adult and pediatric patients with hemophilia A for routine prophylaxis.
Of patients who received cefoperazone-sulbactam, 9.2% reported a coagulation disorder and 15.7% reported a decrease in platelet count.
Inhibitor incidence was found to be 10.2% in previously untreated patients with severe hemophilia B after 500 exposure days.
The most common bleeding disorder in this cohort was von Willebrand disease, which comprised 62.9% of diagnoses.
Researchers conducted a systematic review to assess outcomes and complications in pregnant women with type 3 von Willebrand disease.
Researchers evaluated the diagnostic utility of the ThromboGenomics high-throughput sequencing test for bleeding, thrombotic, and platelet disorders.
Patients with hemophilia had lower median score on the Offer Self-Image Questionnaire compared with a control group.
The majority of patients admitted to the hospital after seeking emergency care for heavy menstrual bleeding did not have an underlying bleeding disorder.
The US FDA has received a BLA for valoctocogene roxaparvovec (BMN 270) for the treatment of hemophilia A in adults.
Although gene therapy shows promise in curing hemophilia, questions about its efficacy, optimal administration, and outcomes remain.
C-reactive protein and urine albumin/creatinine ratio were associated with increased risk of bleeding in patients with thrombocytopenia due to hematologic malignancy.
Patients with hemophilia A reported a median improvement of 2.25 points in hemophilia joint health score during the course of the study.
Risk for postpartum hemorrhage after cesarean delivery was nearly 2-fold greater in patients with mild factor XI deficiency compared with the control cohort.
Researchers evaluated whether simoctocog alfa, a fourth-generation recombinant factor VIII product, is safe and effective in patients with severe hemophilia A.
Median age at inhibitor development was 13 years, and the inhibitor-related mortality rate was 2.44 per 1000 person-years.
Of 69 patients referred for hemostatic examination due to severe postpartum hemorrhage, 16 (23%) were diagnosed with a mild bleeding disorder.
Researchers calculated the optimal values for parameters of the ROTEM sigma-based algorithm for treating coagulopathic bleeding.
Antiplatelet therapy is used to manage cardiovascular events but can lead to increased risk for bleeding events both mild and severe.
Researchers found that many patients have limited knowledge concerning potential serious interactions between dietary supplements and apixaban.
Transfusing activated platelets can increase the number of transfusions required and thus lead to additional costs compared with transfusing resting platelets.